Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies
Top Cited Papers
- 1 January 2013
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 110 (08), 205-212
- https://doi.org/10.1160/th13-02-0150
Abstract
Thrombosis and Haemostasis publishes original basic research and clinical studies in vascular biology and medicine, serving as an international platform for dissemination and debate of scientific information at the cutting edge.Funding Information
- Digestive Disease Research Foundation
This publication has 38 references indexed in Scilit:
- Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for ThromboprophylaxisOrthopedics, 2012
- Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillationInternational Journal of Clinical Practice, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral AnticoagulantJournal of Medical Toxicology, 2011
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialThe Lancet, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and HumansDrug Metabolism and Disposition, 2009
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansDrug Metabolism and Disposition, 2008
- The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in HumansDrug Metabolism and Disposition, 2007